Literature DB >> 4823268

Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man.

H S Smith, D M Taylor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4823268

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  15 in total

1.  Preclinical imaging characteristics and quantification of Platinum-195m SPECT.

Authors:  E A Aalbersberg; B J de Wit-van der Veen; O Zwaagstra; K Codée-van der Schilden; E Vegt; Wouter V Vogel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-11       Impact factor: 9.236

Review 2.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 3.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

4.  Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin.

Authors:  B Hecquet; P Vennin; C Fournier; J L Lefebvre; A Caty; J Bonneterre; L Adenis; A Demaille
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Cisplatin disposition in children and adolescents with cancer.

Authors:  W R Crom; W E Evans; C B Pratt; N Senzer; M Denison; A A Green; F A Hayes; G C Yee
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.

Authors:  L Pendyala; W Greco; J W Cowens; S Madajewicz; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia.

Authors:  H Gerad; M J Egorin; M Whitacre; D A Van Echo; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II).

Authors:  R Harrison; C A McAuliffe; A Zaki; J Baer; H Sharma; A Smith; H Jackson; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 10.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.